CF
RYTM icon

Corebridge Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Corebridge Financial’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,821
Closed -$1.42M – 2262
2025
Q1 		$1.42M Sell
26,821
-399
-1% -$22.1K 0.01% 1117
2024
Q4 		$1.52M Sell
27,220
-2,054
-7% -$113K 0.01% 1131
2024
Q3 		$1.53M Sell
29,274
-180
-0.6% -$8.63K 0.01% 1161
2024
Q2 		$1.21M Buy
+29,454
New +$1.18M 0.01% 1238

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Corebridge Financial's RYTM Position: Q2 2025 in Review

Corebridge Financial sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 26,821 shares — an estimated $1.42M sold.

Corebridge Financial first reported a position in RYTM in Q2 2024 and held it in 4 quarters. The position peaked at $1.53M in Q3 2024. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • Corebridge Financial reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 26,821 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $1.42M.
  • Corebridge Financial first reported a position in Rhythm Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Rhythm Pharmaceuticals position peaked at $1.53M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.